$GNVR News
Last published 3mo ago
- 3mo agoGNVRGenvor’s Antimicrobial Peptides Advance into Sugar Beet ResearchGlobeNewswireWoodland, CA, July 27, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB:GNVR) ("Genvor"), a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture
- 5mo agoGNVRGenvor Appoints Donald Kalkofen as Chief Financial OfficerGlobeNewswireWoodland, CA, May 21, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB:GNVR) ("Genvor"), a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human
- 7mo agoGNVRGenvor Announces Strategic Memorandum of Understanding with Canlab International™ to Advance Commercial Peptide PipelineGlobeNewswireWoodland, CA, April 14, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB:GNVR), a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health
- 8mo agoGNVRGenvor Announces Strategic Expansion into Health and Wellness Market, Leveraging Proprietary AI-Accelerated BioCypher Platform to Develop Consumer Peptide SolutionsGlobeNewswireWoodland, CA, March 04, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB:GNVR), a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health,
- 9mo agoGNVRGenvor's AGM182 Antifungal Peptide Technology Validated in Peer-Reviewed Publication in PhytoFrontiers™GlobeNewswireWoodland, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB:GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, today announced the publication of peer-reviewed research
- 9mo agoGNVRGenvor Appoints Dr. George Stavrides as Executive Vice President, Business Development & CommercializationGlobeNewswireWoodland, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB:GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, today announced the appointment of Dr. George Stavrides as
- 9mo agoGNVRGenvor, Inc. to Present at the 3rd Annual DealFlow Discovery ConferenceGlobeNewswireWoodland, CA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTC:GNVR), a biotechnology company pioneering AI-accelerated peptide technology for sustainable agriculture, today announced that it will participate in the
- 11mo agoBICXDTCFFECHQFGNVR+4Life Sciences Virtual Investor Forum Agenda Announced for December 11thGlobeNewswireNEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for the Life Sciences Virtual Investor Forum to be held December 11th.
- 11mo agoGNVRGenvor to Present at the Life Sciences Virtual Investor Forum December 11thGlobeNewswireWOODLAND, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB:GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, today announced that Chad Pawlak, Chief Executive Officer, will
- 12mo agoGNVRGenvor Announces Issuance of New U.S. Patent for Corn with Antifungal PeptideGlobeNewswireWoodland, CA, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB:GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, announced today the United States Patent and Trademark Office
- 1y agoGNVRGenvor Restores Trading Status and Expands Global Collaborative Research NetworkGlobeNewswireWoodland, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCID: GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, today announced that it has regained active OTCQB trading status